Month: November 2024

Posted on | Posted on John Murphy | Leave a Comment on Ideological diversity of media consumption predicts COVID-19 vaccination

Ideological diversity of media consumption predicts COVID-19 vaccination

Marrissa D. Grant, David M. Markowitz, David K. Sherman, et. al., Scientific Reports volume 14, Article number: 28948 (2024)  Abstract This study examines the relationship between respondents’ vaccine hesitancy, reported media consumption patterns, ideological leanings, and…[...]

Read More
Posted on | Posted on John Murphy | Leave a Comment on Evidence on Long COVID Diagnosis, Risk, Symptoms, and Functional Impact for Patients

Evidence on Long COVID Diagnosis, Risk, Symptoms, and Functional Impact for Patients

News Release |  2024, National Academies of Sciences, Engineering, and Medicine WASHINGTON — A new report from the National Academies of Sciences, Engineering, and Medicine presents conclusions about Long COVID diagnosis, symptoms, and…[...]

Read More
Posted on | Posted on John Murphy | Leave a Comment on Study Censored by The Lancet Finally Released: Confirms ‘High Likelihood of Causal Link Between COVID-19 Vaccines and Death’

Study Censored by The Lancet Finally Released: Confirms ‘High Likelihood of Causal Link Between COVID-19 Vaccines and Death’

On November 17, 2024, Science, Public Health Policy and The Law journal published a peer-reviewed study titled, “A Systematic Review Of Autopsy Findings In Deaths After Covid-19 Vaccination.“ This study…[...]

Read More
Posted on | Posted on John Murphy | Leave a Comment on NIH to open long COVID clinical trials to study sleep disturbances, exercise intolerance, and post exertional malaise

NIH to open long COVID clinical trials to study sleep disturbances, exercise intolerance, and post exertional malaise

Part of the NIH RECOVER Initiative, trials will test four treatments. The National Institutes of Health (NIH) will launch clinical trials to investigate potential treatments for long-term symptoms after COVID-19…[...]

Read More
Posted on | Posted on John Murphy | Leave a Comment on Persistence of SARS CoV-2 S1 Protein in CD16+ Monocytes in Post-Acute Sequelae of COVID-19 (PASC) up to 15 Months Post-Infection

Persistence of SARS CoV-2 S1 Protein in CD16+ Monocytes in Post-Acute Sequelae of COVID-19 (PASC) up to 15 Months Post-Infection

Authors: Bruce K. Patterson, 1 , * Edgar B. Francisco, 1 Ram Yogendra, 2 et. al., Front Immunol. 2021; 12: 746021.Published online 2022 Jan 10. doi: 10.3389/fimmu.2021. 746021PMCID: PMC8784688PMID: 35082777 Abstract The recent COVID-19 pandemic is a treatment challenge in the acute…[...]

Read More
Posted on | Posted on John Murphy | Leave a Comment on Mesenteric Panniculitis and COVID-19: A Rare Association

Mesenteric Panniculitis and COVID-19: A Rare Association

Authors: Israa A Alyousef,1Zainab A Alsaileek,1Manar A Alabdulsalam,1et. al. Cureus. 2022 Jan; 14(1): e21314. . doi: 10.7759/cureus.21314 PMCID: PMC8849467PMID: 35186573 Abstract Coronavirus disease 2019 (COVID-19) typically involves the respiratory system, but gastrointestinal involvement is common.…[...]

Read More
Posted on | Posted on John Murphy | Leave a Comment on Role of 2-Deoxy-D-Glucose in Enhancing the Efficacy of Standard of Care for Moderate to Severe COVID-19: A Comparative Analysis of Clinical Outcomes

Role of 2-Deoxy-D-Glucose in Enhancing the Efficacy of Standard of Care for Moderate to Severe COVID-19: A Comparative Analysis of Clinical Outcomes

Triven Sagar Sandepogu • Chennakesavulu Dara • Saranya Mallamgunta •, et. al. DOI: 10.7759/cureus.73993  Abstract Objective This study aimed to evaluate the role of 2-Deoxy-D-Glucose (2-DG) in moderate to severe Coronavirus Disease 2019 (COVID-19) cases. Methodology…[...]

Read More